Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse 21:00:02 17/07/2024 BST After market 21:19:23
156.6 USD +3.69% Intraday chart for Johnson & Johnson 156.6 0.00%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Sector Update: Health Care Stocks Advance Late Afternoon MT
Fed Governor's Remarks, Earnings Leave Equities Mixed MT
Stifel Raises Johnson & Johnson's Price Target to $160 From $155 MT
Nasdaq plunges, hit by tumbling chips, megacaps; Dow extends rally RE
Sector Update: Health Care Stocks Higher Wednesday Afternoon MT
Sector Update: Health Care MT
Fed Governor Waller's Comments, Earnings Leave Equities Mixed; Nvidia Slides MT
Megacap tech, chip stock rout drags Nasdaq to two-week low; Dow outperforms RE
Global markets live: Adidas, TSMC, Vale, HSBC, J&J... Our Logo
Top Midday Stories: Chip Stocks Fall; MBA US Mortgage Applications Rebound; Johnson & Johnson, Elevance Health Q2 Earnings Rise; Prologis Posts Q2 Beat; VF to Sell Supreme Brand to EssilorLuxottica MT
Stocks in motion: VF Corp and Johnson & Johnson stand out Our Logo
Trending : Johnson & Johnson Beats 2Q Sales Guidance DJ
Johnson & Johnson Cuts Full-Year Earnings Outlook Following Second-Quarter Beat MT
Earnings reports take center stage as tech stocks tumble Our Logo
Sector Update: Health Care Stocks Lean Lower Premarket Wednesday MT
Wall Street set to fall as megacap chip, tech stocks tumble RE
Transcript : Johnson & Johnson, Q2 2024 Earnings Call, Jul 17, 2024
Genmab, J&J Log Higher Q2 Sales for Blood Cancer Drug Darzalex MT
Stock Futures Decline as Traders Await More Earnings; Asia, Europe Churn MT
Johnson & Johnson Maintains Quarterly Dividend at $1.24 per Share, Payable Sept. 10 to Shareholders of Record on Aug. 27 MT
J&J: Quarterly adjusted EPS up 10.2 CF
Johnson & Johnson Q2 Adjusted Earnings, Revenue Rise; Lowers Full-Year Earnings Guidance MT
Johnson & Johnson Announces Quarterly Cash Dividend for Third Quarter of 2024, Payable on September 10, 2024 CI
Earnings Flash (JNJ) JOHNSON & JOHNSON Posts Q2 Revenue $22.45B MT
Earnings Flash (JNJ) JOHNSON & JOHNSON Reports Q2 EPS $2.82 MT
Chart Johnson & Johnson
More charts
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
151 USD
Average target price
171.5 USD
Spread / Average Target
+13.56%
Consensus
  1. Stock Market
  2. Equities
  3. JNJ Stock
  4. News Johnson & Johnson
  5. Sector Update: Health Care Stocks Higher Wednesday Afternoon